Eberle Schultz, Counsel, O'Melveny & Myers LLP to Speak at TKG’s BPCIA Patent Dance: Navigating the Biosimilar Litigation Landscape in 2020 Webcast
The Knowledge Group, the leading producer of regulatory focused webcasts, has announced today that Eberle Schultz, Counsel, O'Melveny & Myers LLP will speak at its webcast entitled, “BPCIA Patent Dance: Navigating the Biosimilar Litigation Landscape in 2020.” This event is scheduled for February 6, 2020, from 3:00 pm to 4:00 pm (ET).
- (1888PressRelease) February 03, 2020 - For further details, please visit:
https://www.theknowledgegroup.org/webcasts/bpcia-patent-dance/
About Eberle Schultz
Eberle Schultz is a Counsel at O’Melveny & Myers where she practices complex patent litigation within the biotechnology, pharmaceutical, and chemical industries. Eberle counsels life sciences clients in all aspects of patent litigation to help businesses achieve their strategic goals.
Eberle represents innovator pharmaceutical companies in patent ligation under the Hatch-Waxman Act and is experienced in innovator declaratory judgement actions, inter partes review proceedings before the Patent Trial and Appeal Board, Federal Circuit appeals, licensing disputes, and patent validity opinions. She has litigated a variety of technologies, including multiple anti-cancer therapies and biologics.
About O'Melveny & Myers LLP
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at omm.com.
Event Synopsis:
Since the beginning of 2019, the number of biosimilar litigation - particularly those concerning the Biologics Price Competition and Innovation Act (BPCIA) “patent dance” - has drastically increased. One of the notable BCPIA cases that are being closely watched, is Amgen’s legal battle with Novartis’ Sandoz arm over the Enbrel patent, in which the former intends to hold commercial exclusivity for Enbrel until 2029. The legal precedents established in this dispute are expected to impact the biosimilar market as well as the pending and future biosimilar patent lawsuits.
With the changing biosimilar landscape and stiffer competition in the backdrop, counsel to drug companies should keep an eye out for these lawsuits and other legal developments to devise effective patent management and litigation strategies.
Listen to patent experts, Sean Sheridan (Charles River Associates) and Eberle Schultz (O'Melveny & Myers LLP) as they provide the audience with an in-depth analysis of the recent biosimilar litigation trends relating to the BPCIA patent dance. Speakers will also offer the best patent management and litigation practices in light of the recent developments.
This LIVE Webcast will discuss the following key provisions:
• The BPCIA Patent Dance – Statistics and Recent Trends
• Notable Cases and Court Decisions
• Best Patent Management Practices
• Effective Litigation Strategies
• Outlook
About The Knowledge Group
The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam